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A B S T R A C T
Bovine tuberculosis (BTB) is a disease of economic and zoonotic importance caused mainly byMycobacterium bovis. In
addition to the tuberculin skin test, an interferon-gamma (IFN-γ) release assay (IGRA) blood test has been incorporated
in the BTB control programs of numerous countries as an ancillary test to the skin test. A potential disadvantage of the
IGRA assay is that it relies solely on the measurement of a single readout (i.e. IFN-γ) for the detection of BTB. In this
study we have assessed the practical use of CXCL10 as an additional biomarker for the diagnosis of BTB in the setting
of the current testing approach alongside IGRA. To do so, we have assessed both IFN-γ and CXCL10 readouts in blood
cultures from a variety of different BTB cattle groups stimulated with standard tuberculin reagents and also with more
specific defined antigens (ESAT-6, CFP-10 and Rv3615c). When using a tuberculin based whole blood assay, CXCL10
alone could not substitute for IFN-γ as the analyte measured in the test without reducing the sensitivity of detecting
BTB animals. However, when used as an additional test readout, CXCL10 identified BTB animals that failed to induce
IFN-γ responses. When tested in non-infected animals, the use of the dual biomarker system had the potential to lower
overall test specificity, however this could be overcome by raising the cut-off values for CXCL10 test positivity. Taken
together, the results demonstrate that in particular settings, measurement of CXCL10 has the potential to complement
the current use of IFN-γ in blood assays to maximise the detection of BTB.
1. Introduction
Bovine tuberculosis (BTB) is a livestock disease of economic and
zoonotic importance caused by pathogens of the Mycobacterium tu-
berculosis complex, mainly by Mycobacterium bovis (M. bovis). The global
financial burden of BTB has been estimated at $3 billion US dollars an-
nually (Waters et al., 2012a). In Great Britain (GB), the disease continues
to be a challenge to the farming community and its control centres on the
application of the single intradermal comparative cervical tuberculin
(SICCT) skin test and the subsequent removal of animals found to be
positive (reactors). In addition, an interferon-gamma (IFN-γ) release
(IGRA) blood assay using avian and bovine tuberculin has been in-
corporated in the BTB control programs of numerous countries, including
the UK, as an ancillary test to the standard skin test. Used in this way,
IGRA is a useful tool in particular situations such as persistent TB herd
breakdowns, severe TB herd breakdowns (as an alternative to whole herd
slaughter), and confirmed new TB herd breakdowns outside of endemic
BTB areas (de la Rua-Domenech et al., 2006).
Both the SICCT skin test and IGRA assays are conventionally based on
the detection of a cell-mediated immune response to tuberculin test re-
agents, i.e. bovine purified protein derivative (PPD-B) and avian purified
protein derivative (PPD-A). Given that M. avium subsp. paratuberculosis
infection causing Johne’s Disease (Alvarez et al., 2009; Aranaz et al.,
2006) and immunisation with M. avium subsp. paratuberculosis vaccines
(Kohler et al., 2001) can compromise the sensitivity and specificity of
BTB detection when using tuberculin reagents, the use of M. bovis-spe-
cific antigens could mitigate the limitation of PPD in such settings. In-
deed, from October 2017 the defined mycobacterial antigens ESAT-6 and
CFP-10 have been used in GB to increase IGRA test sensitivity in situa-
tions such as herds co-infected with M. avium subsp. paratuberculosis
(Shelley Rhodes, personal communication). Peptide cocktails based on
these antigens, along with another cocktail covering the amino acid se-
quence of the Rv3615c antigen, also form the basis of a blood IFN-γ DIVA
test (Differentiating Infected from Vaccinated Animals) capable of
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identifying M. bovis infected animals in the setting of BCG vaccination
(Sidders et al., 2008; Vordermeier et al., 2001). These antigens can also
be used as DIVA skin test antigens (Jones et al., 2012).
A potential disadvantage of the IGRA assay is that it relies on the
measurement of a single readout (IFN-γ) for the detection of BTB.
Therefore, identification of additional biomarkers for the diagnosis of BTB
has been the focus of several studies. Analysis of mycobacterial antigen
induced mRNA levels in cattle peripheral blood mononuclear cells
(Aranday-Cortes et al., 2012; Blanco et al., 2011; Waters et al., 2012b) or
whole blood (Xin et al., 2018) revealed greater expression of several cy-
tokines/chemokines (including IL-6, IL-17A, IL-22, CXCL9, CXCL10 and
TNF-α) in samples fromM. bovis infected animals compared to uninfected
controls, suggesting that these may be useful diagnostic targets. Indeed,
several human TB studies have demonstrated that CXCL10 (also known as
interferon-gamma inducible protein-10; IP-10) can be used as a bio-
marker of TB, where significantly greater levels of mycobacterial antigen-
induced CXCL10 protein were detected in whole blood of TB patients
compared to healthy controls (Jenum et al., 2016; Wang et al., 2012,
2016; Whittaker et al., 2008). In contrast to measuring mRNA, initial
studies quantitating CXCL10 protein levels inM. bovis-infected cattle were
not promising (possibly due to the use of a human specific CXCL10 ELISA
to quantitate protein levels), where responses to mycobacterial antigens
did not generally exceed responses in non-stimulated cultures (Waters
et al., 2012b). However, subsequent studies using a cattle specific CXCL10
ELISA have shown more promise. In BTB cattle, significantly greater
CXCL10 responses were seen in whole blood cultures stimulated with
mycobacterial antigens compared to non-stimulated cultures (Parsons
et al., 2016). Furthermore, greater levels of mycobacterial antigen-in-
duced CXCL10 protein were observed in whole blood samples from M.
bovis infected cattle compared to uninfected controls (Parsons et al., 2016;
Xin et al., 2018) and in IGRA positive African buffaloes compared to IGRA
negative controls (Goosen et al., 2015). Although these studies have
identified CXCL10 as a potential biomarker for BTB diagnosis, they have
not addressed or demonstrated whether this provides any additional
benefit over the current use of IGRA tests.
In this study we have assessed the practical use of CXCL10 as a
biomarker for the diagnosis of BTB in the setting of the current testing
approach using IGRA. To do so we have asked the following specific
questions: (i) does CXCL10 provide a more sensitive readout for de-
tecting BTB compared to IFN-γ; and (ii) can CXCL10 complement the
IFN-γ assay to maximise the detection of BTB? We have assessed these
readouts in blood cultures from a variety of different BTB cattle groups
stimulated with standard tuberculin reagents and also the more specific
defined antigens (e.g. ESAT-6, CFP-10 and Rv3615c).
2. Materials and methods
2.1. Animals
Blood and/or whole blood culture plasma supernatants were ac-
quired from animals from several independent sources:
Group A: Blood from cattle naturally infected with BTB, identified
as skin test reactors during routine UK BTB surveillance operations and
recruited to APHA Weybridge (n=20). All animals also tested positive
in the tuberculin-based IGRA assay. Post-mortem examinations were
performed on all these animals and M. bovis infection confirmed by
pathology and/or culture.
Group B: Blood from TB negative cattle sourced from farms with no
known history of BTB and in BTB-free areas, which were recruited to
studies at APHA Weybridge (n= 55).
Group C: Blood from cattle naturally infected with BTB, identified as
tuberculin IGRA positive cattle from a UK herd tested during routine UK
BTB surveillance operations (n=22).
Group D: Whole blood culture plasma supernatant from tuberculin
IGRA positive cattle identified during routine UK BTB surveillance
operations (supplied by APHA Scientific Laboratories Services routine
diagnostic laboratories, n= 71).
Group E: Whole blood culture plasma supernatant from SICCT po-
sitive cattle in herds with current active outbreaks of BTB in the
Republic of Ireland (n=124).
Group F: Blood from cattle on BCG vaccination/M. bovis infection
studies at APHA Weybridge (Dean et al., 2015; Jones et al., 2017)
which were IFN-γ negative to the DIVA antigens ESAT-6/CFP10 and
Rv3615c but confirmed as M. bovis infected by pathology and/or cul-
ture (n=18).
2.2. Ethics statement
Cattle in groups A, B and F were experimental animals on studies
conducted at APHAWeybridge. The animal procedures for these studies
were approved by the Animal and Plant Health Agency (APHA) Animal
Welfare and Ethical Review Body. For group E animals, the SICCT and
collection of blood samples on which the blood IFN-γ tests were carried
out was conducted as part of the Irish national BTB eradication pro-
gramme, which is subject to the EU trade Directive 64/432/EEC, and
which governs the nature and frequency of testing. Blood sample testing
was approved by the UCD Animal Research Ethics Committee (AREC-E-
16-34-Gormley).
2.3. Blood stimulation
With the exception of group E, heparinised blood samples from all
other groups were stored overnight at room temperature before sti-
mulation for 20 to 24 h at 37 °C in 5% CO2 with the following: bovine
and avian tuberculin (PPD-B and PPD-A; Prionics, Lelystad,
Netherlands), PPD-B 300U/ml final concentration; PPD-A 250U/ml
final concentration; positive mitogen control of pokeweed mitogen
(Sigma, UK) at 10 μg/ml final concentration or a negative control of
RPMI-1640 (Gibco, UK) alone. In some groups, blood samples were also
stimulated with two specific-antigen peptide cocktails: ESAT-6/CFP-10
and Rv3615c, both at 5 μg/ml/peptide final concentration (synthetic
peptides produced by Pepceuticals, Enderby, UK). After stimulation,
blood was centrifuged at 300 g for 10min and the plasma supernatant
was harvested and stored at −80 °C until required.
For group E whole blood was collected into heparin tubes (BD
Medica, Dublin, Ireland) and submitted to the laboratory within 24 h.
Aliquots of the heparinised blood (1.5ml) were dispensed into in-
dividual wells of 24-well tissue culture plates (Cruinn, Ireland) con-
taining either PPD-B (20 μg/ml final concentration), PPD-A (10 μg/ml
final concentration) for in vitro antigen stimulation or phosphate buf-
fered saline (PBS) for a non-stimulated control. The tuberculin used for
antigen stimulation was from the same production batch as for the
SICCT (Thermo-Fisher Scientific, Lelystad, Netherlands). These cultures
were incubated for 18 h at 37 °C in a humidified atmosphere with 5%
CO2. The stimulated blood was centrifuged at 1500 g for 15min and the
plasma supernatant was harvested and stored at −20 °C until required.
In all groups, the time delay between collecting and stimulating the
blood samples was included so that the conditions in this study re-
flected as closely as possible the protocol for the current whole blood
IGRA assay used in GB (i.e. next day testing). Blood processing and
stimulation methods were consistent with the Bovigam® test kit in-
structions and the OIE Manual of Diagnostic Tests and Vaccines for
Terrestrial Animals 2018.
2.4. Interferon-gamma release assay
The production of IFN-γ in each sample was measured using the
Bovigam® test kit following manufacturer’s instructions (Thermo Fisher
Scientific). Samples were tested in duplicate and the IFN-γ concentra-
tions were taken as the optical density (OD) reading at 450 nm as
measured on a Multiskan Ascent (Thermo Labsystems) plate reader.
Test results were taken as the PPD-B stimulated value minus the PPD-A
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stimulated value (ΔPPD), or ESAT-6/CFP-10 and Rv3615c values minus
the unstimulated control value. Results greater than or equal to 0.1
were taken as a positive response.
2.5. CXCL10 ELISA
CXCL10 in plasma samples was measured as follows. Nunc
MaxiSorb flat-bottom 96 well plates were coated overnight at 4 °C with
100 μl/well anti-bovine CXCL10 polyclonal antibody (1 μg/ml,
Kingfisher Biotech, St Paul, MN, USA) in carbonate-bicarbonate buffer
pH9.6. Between subsequent steps, wells were washed with wash buffer
(PBS with 0.05% Tween 20) and all further steps were undertaken at
room temperature. Wells were blocked for 1 h with 200 μl/well PBS
with 3% bovine serum albumin (BSA, Sigma). After blocking, plasma
samples (diluted 1 in 2 in assay buffer, PBS with 1% BSA) were in-
cubated in duplicate wells for 2 h (100 μl/well). After washing, plates
were incubated for 1 h with 100 μl/well biotinylated anti-bovine
CXCL10 polyclonal antibody (Kingfisher Biotech, 0.2 μg/ml in assay
buffer). A further wash was followed by incubation for 30min with
100 μl/well Streptavidin-horseradish peroxidase (GE Healthcare, UK)
diluted 1:2000 in assay buffer. After a final wash step, 100 μl of Tetra-
methylbenzidine (Sigma) was added to each well for up to 15min be-
fore colour reactions were stopped with 100 μl/well 0.5 M sulphuric
acid. The OD of each reaction was measured at 450 nm and the con-
centration of CXCL10 in each sample was calculated by comparing the
OD reading against a standard curve generated on each plate using a
dilution series of recombinant CXCL10 (Kingfisher Biotech). Test results
were taken as the PPD-B stimulated value minus the PPD-A stimulated
value (ΔPPD), or ESAT-6/CFP-10 and Rv3615c values minus the un-
stimulated control value.
2.6. Statistical analysis
Statistical analysis was performed using GraphPad Prism 7 software
(GraphPad Software Inc.). Cut-offs for differentiating between groups
were determined using Receiver Operator Characteristic (ROC) curves.
Comparison of test relative sensitivities was performed using the Fisher
exact test using one-sided or two-sided analysis where appropriate.
3. Results
CXCL10 ELISA data from 20 field reactors with confirmed BTB in-
fection (group A) and 55 non-infected cattle (group B) were subjected
to ROC analysis to determine positive/negative cut-offs for stimulation
with ΔPPD, ESAT-6/CFP-10 or Rv3615c peptide cocktails (Fig. 1). All
three stimuli gave significant areas under the curve, suggesting that
CXCL10 may show a potential as a readout cytokine capable of dis-
tinguishing between BTB infected and non-infected control animals
when using these test reagents. As we were initially interested in seeing
if CXCL10 is able to replace IFN-γ as a readout in blood tests for BTB,
cut-offs for CXCL10 positivity at a predetermined specificity of approx.
96% was chosen since this most closely represented the specificity of
the Bovigam IFN-γ test (de la Rua-Domenech et al., 2006). At this level
of specificity, cut-offs of 1.204 ng/ml, 0.685 ng/ml and 1.638 ng/ml
were obtained for ΔPPD, ESAT-6/CFP-10 and Rv3615c respectively.
Having defined the cut-offs for the specific test reagents, these were
used to compare the sensitivity of the CXCL10 readout to that of IFN-γ
in detecting BTB infected animals, which had been designated as in-
fected by either a previous positive TB skin test reaction (group A) or a
positive IGRA result (group C and D). To do so, CXCL10 and IFN-γ levels
in samples from the same whole blood culture were analysed. Our in-
itial investigations focused on the tuberculin test reagents (ΔPPD re-
sponse), as these are used in the routine testing setting. As shown in
Table 1, all 19 of the SICCT positive animals (group A) tested gave
positive blood responses using IFN-γ as a readout (relative sensitivity of
100%, 95% CI 83–100%), while 17 were positive when using CXCL10
Fig. 1. Significant areas under the curve (AUC) for CXCL10 production in
Receiver Operator Characteristic (ROC) curve analysis. ROC curves show the
accuracies of (A) ΔPPD, (B) ESAT-6/CFP-10 and (C) Rv3615c induced CXCL10
production at distinguishing between TB reactor animals and uninfected con-
trols. * p < 0.0001 (ROC curve analysis for AUC).
Table 1
Test positive outcomes using tuberculin (ΔPPD) induced IFN-γ and CXCL10
readouts.
Test positive animals (% relative sensitivity)
Readout Group A (n= 19) Group C (n=22) Group D (n= 71)
IFN-γ 19 (100%) 22 (100%) 71 (100%)
CXCL10 17 (89%) 9 (41%)* 31 (44%)*
* p < 0.0001, two-sided Fisher exact test (compared to IFN-γ).
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(relative sensitivity of 89%, 95% CI 69–98%). As expected, all group C
and group D animals tested positive in the blood test using IFN-γ, with
relative sensitivities of 100% (95% CI 85–100% and 95% CI 95–100%
respectively). In contrast, significantly smaller proportions of group C
(9 out of 22) and group D (31 out of 71) animals tested positive using
CXCL10, resulting in relative sensitivities of 41% (95% CI 23–61%) and
44% (95% CI 33–55%) respectively.
Although the results suggested CXCL10 could not substitute for IFN-
γ as a test readout for the tuberculin whole blood assay, we next in-
vestigated whether it had potential as an additional readout to com-
plement IFN-γ to maximise overall test sensitivity for the detection of
M. bovis infection. To this end, we tested samples from 124 tuberculin
skin test positive cattle in herds with current active outbreaks of BTB
(group E). The samples were first screened with the standard IFN-γ
assay, which revealed 84 test positive cattle. We then quantified
CXCL10 levels in the remaining 40 samples that were not detected by
the IFN-γ assay, which revealed a further 6 animals as test positive
(Fig. 2). This improved the relative sensitivity of diagnosis in this set-
ting from 68% (95% CI 59–75%) to 73% (95% CI 64–80%).
Having shown that CXCL10 has the potential to improve test sen-
sitivity using conventional tuberculin reagents, we next investigated a
similar role when specific antigens were used to stimulate whole blood.
To this end, we used a cocktail of overlapping peptides covering the
amino acid sequence of the immune-dominant antigens ESAT-6 and
CFP-10. In addition, we investigated responses to a peptide cocktail
covering the amino acid sequence of the antigen Rv3615c, as this has
previously been shown to be useful in detecting infected animals that
fail to respond to ESAT-6/CFP-10 (Sidders et al., 2008). When group A
animals (SICCT positives) were considered, measurement of CXCL10
did not identify any additional test positives to the ESAT-6/CFP-10
peptide cocktail (Table 2). In contrast, a readout of IFN-γ and/or
CXCL10 (compared to IFN-γ alone) identified an additional 2 animals
testing positive to the Rv3615c peptide cocktail, resulting in an increase
in relative sensitivity from 58% (95% CI 36–77%) to 68% (95% CI
46–85%). Significant improvement in relative test sensitivity was ob-
served for both ESAT-6/CFP-10 and Rv3615c peptide cocktails in group
C animals (ΔPPD IGRA positives). Six additional ESAT-6/CFP-10 test
positive animals were identified using the IFN-γ and/or CXCL10
readout (compared to IFN-γ alone), resulting in an increase in relative
sensitivity from 64% (95% CI 43–80%) to 91% (95% CI 72–98%). Only
1 group C animal tested positive to Rv3615c using IFN-γ alone (relative
test sensitivity of 5%, 95% CI 0–22%), which increased to 6 when using
the IFN-γ and/or CXCL10 readout (relative test sensitivity of 27%, 95%
CI 13–48%). The ESAT-6/CFP-10 and Rv3615c peptide cocktails were
designed for use in an IFN-γ blood DIVA test to identify BCG vaccinated
animals that were not fully protected from infection with M. bovis (as
determined by the presence of pathology at post mortem and/or culture
of M. bovis from lymph node/lung tissue). From previous BCG vacci-
nation / challenge experiments, we identified 18 confirmed infected
animals that tested negative to these antigens when using IFN-γ as the
test readout (group F animals). Of these, four animals were identified as
ESAT-6/CFP-10 test positive when CXCL10 was used as an additional
test readout (Table 2). Taken together, combining the data from all
three groups highlighted the additional benefit of measuring CXCL10 to
maximise the sensitivity of blood tests using specific antigens.
4. Discussion
Traditional IGRA assays for BTB are based on the detection and
comparison of IFN-γ production to PPD-B and PPD-A. Using a similar
approach, the CXCL10 readout failed to achieve a detection rate
matching that for IFN-γ (Table 1), suggesting that a general replace-
ment of an IFN-γ based readout by CXCL10 is not a viable option in
blood-based assays for BTB. In agreement, a previous study in African
buffaloes also demonstrated that CXCL10 based tests failed to identify
all animals disclosed by a positive IFN-γ test (Goosen et al., 2015). Only
one other reported study has investigated the diagnostic potential of
CXCL10 for BTB in cattle (Parsons et al., 2016), where the ΔPPD
CXCL10 readout identified all IGRA positive animals. In this study, the
relative sensitivity of CXCL10 was evaluated using SICCT positive IGRA
positive cattle, which would be equivalent to our group A animals
where we also see the best relative sensitivity for CXCL10.
As shown in Table 1, CXCL10 showed the lowest potential for di-
agnosing infection in SICCT negative IGRA positive animals (groups C
and D). Taking the results from several studies (Coad et al., 2008;
Gormley et al., 2006; Lahuerta-Marin et al., 2015; Neill et al., 1994;
Pollock et al., 2005) it is likely that these SICCT negative IGRA positive
animals may be at an earlier stage of infection compared to SICCT
positive IGRA positive animals (i.e. group A). Indeed, all group A ani-
mals showed evidence of disease pathology (visible lesioned; VL) at
post mortem investigation. In contrast, only 30 of the 71 group D
Fig. 2. Tuberculin-induced CXCL10 complements IFN-γ for the detection of
BTB. CXCL10 levels were quantified in ΔPPD stimulated blood cultures from 40
tuberculin skin test (SICCT) positive animals (Group E) that tested negative
using the IFN-γ readout. Circles represent individual samples and the horizontal
line denotes the cut-off for positivity (set at 1.204 ng/ml).
Table 2
Test positive outcomes using specific antigen induced IFN-γ and CXCL10 readouts.
Test positive animals (% relative sensitivity)
Readout Group A (n=19) Group C (n= 22) Group F (n= 18) Combined (n= 59)

















































a E6/C10 refers to the ESAT-6/CFP-10 peptide cocktail.
b p < 0.05, one-sided Fisher exact test (compared to IFN-γ).
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animals were VL (data not shown). When CXCL10 responses were
compared between group D VL and NVL (non-visible lesioned) animals,
a significantly greater proportion (p < 0.05, Fisher exact test) of test
positive results were observed in VL (18 out of 30) compared to NVL
(13 out of 41) animals (data not shown). Interestingly, these results are
similar to those previously observed for IL-2 responses (Rhodes et al.,
2014). Thus, although CXCL10 may not be sufficient to replace IFN-γ as
a readout in blood assays for BTB, it may provide additional informa-
tion with regards to disease pathology.
An alternative way in which CXCL10 could be used as a diagnostic
tool is to maximise the potential of blood-based assays by detecting
infected animals that tested negative using the standard IFN-γ readout.
For tuberculin induced responses, we were limited to analysing animals
in group E (SICCT positives), as all animals in groups A, C and D already
gave positive ΔPPD IFN-γ responses. Of the 40 group E animals which
tested negative for ΔPPD IFN-γ, 6 gave a positive response to CXCL10
(Fig. 2), demonstrating the potential of this biomarker to complement
IFN-γ. This potential could be further enhanced if a cut-off for positivity
predicted by the ROC curve analysis to give 100% sensitivity was used.
In this case, a further 2 animals negative for ΔPPD IFN-γ gave CXCL10
responses (data not shown). Although altering the cut-off resulted in a
decrease in overall CXCL10 test specificity (a decrease from 96% to
91%), it is possible that this may still remain high enough in situations
where maximal sensitivity for detecting infection is required.
A real benefit for the use of additional biomarker readouts is in the
context of assays that utilise specific mycobacterial antigens (ESAT-6,
CFP-10 and Rv3615c), where detection of infection may not be as
sensitive compared to tuberculin reagents (Sidders et al., 2008;
Vordermeier et al., 2001). Although not improving detection of ESAT-
6/CFP-10 responses, the additional measurement of CXCL10 did iden-
tify 2 extra test positives to the Rv3615c peptide cocktail in group A
animals (Table 2). The measurement of CXCL10 appeared to play a
greater diagnostic role in group C animals, where additional responders
to both peptide cocktails were identified.
Cattle vaccination is being considered as part of BTB control stra-
tegies, and currently the only potentially available vaccine is BCG
(bacille Calmette Guérin). As BCG vaccination is not fully protective in
all cattle (Vordermeier et al., 2016), a diagnostic test will be required to
identify BCG-vaccinated cattle that develop BTB upon exposure to M.
bovis. Unfortunately, BCG vaccination compromises the specificity of
current tuberculin-based diagnostic tests (Berggren, 1981; Buddle et al.,
1995, 1999) and so a blood DIVA IFN-γ test using the ESAT-6/CFP-10
and Rv3615c peptide cocktails has been developed (Vordermeier et al.,
2016). However, as this test is not 100% sensitive, there is potential for
BCG vaccinated animals that are not fully protected from BTB to escape
detection. We identified samples from 18 such animals from previous
vaccination/challenge experiments (Dean et al., 2015; Jones et al.,
2017) and demonstrated that additional measurement of CXCL10 could
disclose a proportion of these animals as test positive (Table 2, group
F), highlighting the potential for applying the CXCL10 assay in parallel
with IFN-γ for the diagnosis of BTB in settings where tuberculin-based
reagents cannot be used.
There are some technical and practical issues related to the CXCL10
assay that may still need to be addressed. As previously described
(Parsons et al., 2016; Waters et al., 2012b), we also observed high levels
of spontaneous CXCL10 production in the unstimulated control cultures
from some animals (data not shown). Given that a comparative readout
of CXCL10 production in peptide-stimulated cultures minus nil-antigen
control cultures is used when evaluating responses to the ESAT-6/CFP-
10 and Rv3615c peptide cocktails, this spontaneous release may limit
the full diagnostic potential of CXCL10 in this setting. Furthermore,
given that neither the IFN-γ nor the CXCL10 test readouts are set to
100% specificity, the use of a dual biomarker system may also com-
promise overall test specificity. When the production of both bio-
markers were analysed in whole blood cultures from 50 control non-
infected cattle (group B animals, data not shown), no positive IFN-γ
responses were seen to any of the test reagents (ΔPPD, ESAT-6/CFP-10
and Rv3615c peptide cocktails), whereas 2 positive CXCL10 test out-
comes were observed with each of the three different stimuli. Using the
ROC curve analysis, it is possible to raise the cut-offs for these antigens
to achieve 100% specificity in the CXCL10 assay. Although this resulted
in overall fewer infected animals testing positive for CXCL10, added
benefit in detecting responses to the peptide cocktails was still observed
(Supplemental Table 1).
5. Conclusion
The results presented herein demonstrate that in particular settings
measurement of CXCL10 has the potential to complement the current
use of IFN-γ in blood assays to maximise the detection of BTB. This
beneficial role is particularly evident when detecting responses to less
immunodominant antigens (e.g. Rv3615c) or responses to specific an-
tigen cocktails in animals at a potentially earlier stage of infection (e.g.
group C).
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